Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. Its products include Endotoxin Activity Assay (EAA), Toraymyxin, and proprietary reagents. The EAA is use for the diagnostic of endotoxin activity in human whole blood. The Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. The company was founded on July 29, 1991 and is headquartered in Toronto, Canada.